Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research
- 13 Nov 2018 Planned End Date changed from 30 Sep 2021 to 30 Nov 2020.
- 13 Nov 2018 Planned primary completion date changed from 30 Sep 2021 to 30 Nov 2020.